Trifonova Oxana P, Maslov Dmitry L, Balashova Elena E, Lokhov Petr G
Institute of Biomedical Chemistry, 10 Building 8, Pogodinskaya Street, 119121 Moscow, Russia.
Metabolites. 2023 Jan 1;13(1):67. doi: 10.3390/metabo13010067.
Metabolomics is one of the most promising 'omics' sciences for the implementation in medicine by developing new diagnostic tests and optimizing drug therapy. Since in metabolomics, the end products of the biochemical processes in an organism are studied, which are under the influence of both genetic and environmental factors, the metabolomics analysis can detect any changes associated with both lifestyle and pathological processes. Almost every case-controlled metabolomics study shows a high diagnostic accuracy. Taking into account that metabolomics processes are already described for most nosologies, there are prerequisites that a high-speed and comprehensive metabolite analysis will replace, in near future, the narrow range of chemical analyses used today, by the medical community. However, despite the promising perspectives of personalized metabolomics, there are currently no FDA-approved metabolomics tests. The well-known problem of complexity of personalized metabolomics data analysis and their interpretation for the end-users, in addition to a traditional need for analytical methods to address the quality control, standardization, and data treatment are reported in the review. Possible ways to solve the problems and change the situation with the introduction of metabolomics tests into clinical practice, are also discussed.
代谢组学是最具前景的“组学”科学之一，有望通过开发新的诊断测试和优化药物治疗应用于医学领域。由于在代谢组学中，研究的是生物体生化过程的终产物，这些终产物受到遗传和环境因素的双重影响，因此代谢组学分析可以检测出与生活方式和病理过程相关的任何变化。几乎每一项病例对照代谢组学研究都显示出较高的诊断准确性。鉴于大多数疾病的代谢组学过程已经得到描述，有前提条件表明，在不久的将来，高速且全面的代谢物分析将取代医学界目前使用的范围狭窄的化学分析方法。然而，尽管个性化代谢组学前景广阔，但目前尚无美国食品药品监督管理局（FDA）批准的代谢组学测试。该综述报道了个性化代谢组学数据分析及其对终端用户解释的复杂性这一众所周知的问题，此外还存在对解决质量控制、标准化和数据处理的分析方法的传统需求。文中还讨论了将代谢组学测试引入临床实践以解决这些问题并改变现状的可能途径。
